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OBJECTIVES: Liver transplantation has not increased with the number of patients requiring this treatment,
increasing deaths among those on the waiting list. Models predicting post-transplantation survival,
including the Model for Liver Transplantation Survival and the Donor Risk Index, have been created. Our
aim was to compare the performance of the Model for End-Stage Liver Disease, the Model for Liver
Transplantation Survival and the Donor Risk Index as prognostic models for survival after liver
transplantation.
METHOD: We retrospectively analyzed the data from 1,270 patients who received a liver transplant from a
deceased donor in the state of Sa˜o Paulo, Brazil, between July 2006 and July 2009. All data obtained from the
Health Department of the State of Sa˜o Paulo at the 15 registered transplant centers were analyzed. Patients
younger than 13 years of age or with acute liver failure were excluded.
RESULTS: The majority of the recipients had Child-Pugh class B or C cirrhosis (63.5%). Among the 1,006 patients
included, 274 (27%) died. Univariate survival analysis using a Cox proportional hazards model showed hazard
ratios of 1.02 and 1.43 for the Model for End-Stage Liver Disease and the Model for Liver Transplantation
Survival, respectively (po0.001). The areas under the ROC curve for the Donor Risk Index were always less than
0.5, whereas those for the Model for End-Stage Liver Disease and the Model for Liver Transplantation Survival
were significantly greater than 0.5 (po0.001). The cutoff values for the Model for End-Stage Liver Disease
(Z29.5; sensitivity: 39.1%; specificity: 75.4%) and the Model for Liver Transplantation Survival (Z1.9; sensitivity
63.9%, specificity 54.5%), which were calculated using data available before liver transplantation, were good
predictors of survival after liver transplantation (po0.001).
CONCLUSIONS: TheModel for Liver Transplantation Survival displayed similar death prediction performance to that
of the Model for End-Stage Liver Disease. A simpler model involving fewer variables, such as the Model for
End-Stage Liver Disease, is preferred over a complex model involving more variables, such as the Model for Liver
Transplantation Survival. The Donor Risk Index had no significance in post-transplantation survival in our patients.
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’ INTRODUCTION
Liver transplantation is the treatment of choice for many
terminal hepatic diseases, for which this treatment increases
survival rates and improves quality of life. The 1- and 5-year
survival rates following liver transplantation are currently 80%
and 50%, respectively (1,2). Progressive improvement in
transplantation results has led to an increase in the number of
patients for which organ transplantation is indicated. However,
the insufficient availability of donated organs has limited theDOI: 10.6061/clinics/2015(06)05
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number of procedures that can be performed (1–5). Because of
the growing discrepancy between the numbers of organ donors
and of potential recipients, it has become necessary to establish
operative criteria for selecting the patients and the donors.
Accordingly, a standardized system for classifying the severity
of the patient’s condition as well as the patient’s prognosis has
become necessary for optimizing outcomes.
Various medical scoring systems have been used as
prognostic models of disease severity. For liver disease, the
most widely used model is the Child-Turcotte classification
modified by Pugh et al. (6). The Model for End-Stage Liver
Disease (MELD) scoring system (7) was adopted in the USA
for organ allocation in 2002 and in Brazil in 2006 (8).
Although the MELD is a well-established scale for predicting
the mortality of patients on transplant waiting lists, some
questions remain, particularly with regard to the risk of
death and the relationship between the MELD score and
post-transplantation survival (5,9,10). The Donor Risk Index
(DRI) model (11), which was created via an analysis of 90,882
donors (UNOS/OPT N-USA), identified seven independent
significant risk factors for graft failure in adult recipients.
Finally, the Model for Liver Transplantation Survival (MLTS),
which predicts post-transplantation survival, was developed
as a strong predictor that applies pre-transplantation vari-
ables regarding the donor, the recipient and the surgical team
(12); however, studies and discussion in the medical
literature regarding the MLTS are limited.
Organ allocation should be designed not only to avoid
death before transplantation, but also to prevent premature
post-transplantation deaths and, thus, the waste of scarce
resources. The development of a model capable of predicting
post-transplantation survival has become a matter of vital
interest to the transplant community because a system for
allocating organs that balances disease severity with antici-
pated results can maximize the survival benefits to transplant
patients. A model that can reliably predict patient survival
after a liver transplant is essential. However, it is possible that
other variables that are not considered might affect survival
and reduce the capacity of a particular model to generate
reliable predictions. For this reason, each model must be
validated across multiple centers to confirm its efficacy. Our
aim was to compare the MELD, MLTS, and DRI prognostic
scores relative to post-operative survival outcomes in adult
patients receiving a liver transplant from a cadaver donor.
’ METHODS
We performed a retrospective study analyzing the data
from 1,270 patients who received a liver transplant
performed at 15 institutions in the state of São Paulo, Brazil,
between July 2006 and July 2009 following approval by the
Santa Casa Ethics Committee. Of these 1,270 cases, the
following were excluded from the study:
 Transplants performed on patients younger than 13 years
of age (144/1,270; 11.3%), who were evaluated using the
Pediatric End–Stage Liver Disease scoring system.
 Transplants in patients with acute liver failure, wherein the
criteria of urgency were based on the Kings College or
Clichy models; 92/1,270 (7.2%) patients were evaluated
using these models.
 Transplants on patients with amyloid polyneuropathy
who received ‘‘domino’’ transplants from live donors
(21/1,270; 1.6%).
 Transplants from donors whose data were incomplete;
7/1,270 (0.6%) of the cases had incomplete data for the
donors in the database of the Health Department of the
State of São Paulo.
After excluding the aforementioned cases, our final case
sample consisted of 1,006 transplant patients with an average
age of 51 (13–74) years. Only 30% of the patients were
female. The three most frequent liver disease diagnoses of the
transplant patients were as follows: Child B or C liver
cirrhosis (63.5%), hepatocellular carcinoma (16.3%) and
Child A liver cirrhosis (4.5%).
From the records of the remaining 1,006 patients, we
collected the data of interest to the study and the variables
that constituted the MELD, MLTS, and DRI scores prior to
transplantation. In particular, the following data were
obtained from the Health Department of the State of São
Paulo – which is responsible for collecting and analyzing
data from these 15 transplant centers – and were recorded in
a Microsoft Excel 2007s spreadsheet:
 Recipient data: the record number, age, sex, blood type,
diagnosis, calculated and corrected MELD scores, total
bilirubin level, international normalized ratio (INR) for
blood clotting, sodium level, dialysis, and transplant data;
 Donor data: the record of whether the liver was split, race,
place, age, cause of death, sex, height, and weight; and
 Surgery data: the period of cold ischemia (in hours) and the
period of warm ischemia (in min).
We calculated the MELD, MLTS, and DRI scores for the
final 1,006 patients included in the study using Microsoft
Excel 2007s. Other data of interest to the study included the
retransplant status and the survival duration, which was
measured according to the interval between the transplant
and the date of the last record or the date of death as
recorded by the transplant headquarters of the Health
Department of the State of São Paulo.
Statistical analysis
A Cox proportional hazards (CoxPH) model was used to
identify the relevance of the MELD, MLTS, and DRI scores to
patient mortality. The results were expressed as CoxPH
values with a 95% confidence interval (CI95%). Kaplan-
Meier survival curves were used to analyze the survival
trends over time. The power of the MELD, the DRI, and the
MLTS to predict mortality was evaluated by calculating the
area under the receiver operating characteristic (ROC) curve,
in which a value of 1 represents perfect discrimination
whereas a value of 0.5 represents discrimination that is no
more accurate than chance. Unless otherwise noted, the
mean values are reported with standard deviations (SDs).
Statistical significance was accepted at po0.05. All analyses
were performed using SPSS for Windowss version 13.0, with
the exception of the comparison of the ROC curves, which
was analyzed using Analyse-its 2.12 software.
’ RESULTS
Study characteristics
The means (SDs) of the components of the MELD and
MLTS score formulas were as follows: creatinine level:
1.56 (±1.40) mg/dl; total bilirubin level: 8.29 (±11.31) mg/dl;
INR: 2.10 (±1.48); prothrombin time: 24.81 (±14.80)
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seconds; donor age: 40.79 (±16.10) years; warm ischemia
duration: 49.59 (±15.71) min; and cold ischemia duration:
8.57 (±2.73) hours. The median MELD score was 22.17
(±11.24), and the median MLTS score was 2.07 (±0.74).
The donors had a mean DRI score of 1.44±0.34 and a
mean height of 168.00±12.24 cm. The following parameters
were the most frequent: an age range of 0–39 years (41.8%)
and white race (68.29%); the incidence of a split liver was
only 4.6%. The principal cause of death was stroke (57.75%),
and in 86.8% of the cases, the donor and the transplant
recipient were from the same area.
Analysis of the survival rate and the
prognostic factors
Of the 1,006 patients included in this study, 274 (27%)
died, and the average mortality rate was 0.03 patients per
month based on analysis of the Kaplan-Meier survival curve
(Figure 1A).
We analyzed the relationships between mortality and the
MELD, MLTS, and DRI scores. We performed univariate
survival analyses using a CoxPH model and hazard ratios
(HRs) to identify whether the MELD, MLTS, and DRI scores
were significant prognostic factors for the death of the
patients included in this sample (Table 1). The areas below
the ROC curves for the MELD, MLTS, and DRI scores were
compared for the 7-day, 1-month, 3-month, 6-month, 1-year,
and 2-year post-transplantation survival ratios. The results of
these analyses are presented in Table 2. The ROC curves for
2-year mortality are shown in Figure 1B.
Based on the ROC curves for the MELD, MLTS, and DRI
scores for 2-year survival, we calculated the following
cutoff values:
 MELD: Z29.5 (sensitivity of 39.1% and specificity of
75.4%);
 MLTS: Z1.979 (sensitivity of 63.9% and specificity of
54.5%); and
 DRI: Z2.253 (sensitivity of 4.4% and specificity of 98.6%).
The Kaplan-Meier survival curves significantly differed
between the patients with scores lower than or equal to the
cutoff values for the MELD and the MLTS and those with scores
greater than the respective cutoff values. For the MELD and the
MLTS, the mortality rate of the patients with scores equal to or
above the cutoff value was poorer than that of those with scores
below the cutoff value (Figures 1C and 1D).
Multivariate analysis revealed that the most important
determining factor for mortality according to the MELD
Figure 1 - A) The Kaplan-Meier curve for the survival of 1,006 patients who received a liver transplant in the state of Sa˜o Paulo between
2006 and 2009. B) The ROC curves of the MELD, MLTS, and DRI scores for 2-year mortality for 1,006 liver transplants performed in the
state of Sa˜o Paulo between 2006 and 2009. C) The Kaplan-Meier curves for mortality according to the MELD scores for 1,006 liver
transplants performed in the state of Sa˜o Paulo between 2006 and 2009. D) The Kaplan-Meier curves for mortality according to the
MLTS scores for 1,006 liver transplants performed in the state of Sa˜o Paulo between 2006 and 2009.
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score was the total bilirubin level. For the MLTS score, the
most important determining factors were the total bilirubin
level, the cold and warm ischemia durations, and the
retransplant status (Table 3).
’ DISCUSSION
The most significant of our findings was that the MLTS
yielded a similar outcome to that of the MELD for predicting
post-transplantation mortality (both p=0.001). However, the
DRI did not show a statistically significant association with
post-transplantation mortality (p=0.677).
MELD
The MELD is a well-established (area under the ROC
curve=0.78–0.87) method for estimating the 3-month survival
of patients who do not receive a transplant (5–13). However, its
association with post-transplantation survival is not clear, and
its degree of superiority for non-transplanted patients is
modest and limited (14,15). If the MELD could simultaneously
predict and identify those patients who are at an elevated risk
of dying post-transplantation, its use for allocation would be
supported. The ideal system should not only define the
probability of death without transplantation, but also predict
the risk of death post-transplantation, thus increasing its
utility (16).
The MELD has been reported to predict 3-month mortality in
most candidates on transplant waiting lists (83–87%), reducing
the mortality rate by approximately 3.5% and increasing the
number of transplants for diseases such as hepatocellular
carcinoma by approximately 10%, ranging from 3.1 to 22%
(17,18). Despite its many advantages, the MELD does not
precisely predict survival in 15–20% of cases. The addition of
variables that are good determinants of liver and kidney
function may improve the precision of this model (17).
In this study, we compared the areas under the ROC curve
for post-transplantation survival for the MELD score at
7 days, 1 month, 3 months, 6 months, 1 year and 2 years after
transplantation. The areas under the curve for all of these
time intervals indicated that the MELD-based predictions
were more accurate than chance (i.e., 40.5). This model is
consistently described in the literature as showing good
accuracy (c-statistic=0.78–0.87) in estimating the survival of
patients not receiving a liver transplant. However, the MELD
may be a poor model for predicting post-transplantation
survival, as shown in the study by Jacob in 2004
(c-statistic=0.58) (13). In a study examining 2,565 transplants
from cadaver donors, Desai et al. similarly found that the
MELD showed weak accuracy for predicting 3-month
survival (c-statistic of 0.54; CI95%=0.50–0.59) and 1-year
survival (c-statistic of 0.55; CI95%=0.52–0.59) following
transplantation (19). In this study, the MELD served as a
significant predictor of post-transplantation death (ROC
curve analysis c-statistic=0.59?0.60; CoxPH model: po0.001).
However, our ROC curve for the MELD did not yield a
highly accurate level of agreement (c-statistic=0.8–0.9). These
findings are consistent with those in the literature, as the
MELD is well established for predicting the survival of those
on transplant waiting lists but remains controversial for post-
transplantation survival prediction. For example, our find-
ings were similar to those from a study of 121 patients by
Nagler et al., who obtained a c-statistic for the MELD of 0.61
and showed a relationship between the MELD score and
post-transplantation survival (20).
DRI
Donor characteristics are important factors in determining
transplant outcomes. The DRI considers seven donor
characteristics using the Cox regression model; a lower DRI
score indicates an organ that is closer to ideal for
transplantation (21). Feng et al. (11) summarized the ideal
characteristics of a cadaver donor. Briefly, they found that the
ideal donor was young (o40 years old), was healthy, was tall
(Z1.70 m), experienced brain trauma, was not used for split
Table 1 - The results of univariate survival analysis of the Model for End-Stage Liver Disease, Model for Liver
Transplantation Survival, and Donor Risk Index scores for 1,006 liver transplants performed in the state of Sa˜o Paulo
between 2006 and 2009.
Model B Standard error Wald X2 CoxPH CI95% (CoxPH) p-value
MELD 0.02 0.01 21.28 1.02 1.01 to 1.03 o0.001*
MLTS 0.36 0.08 19.33 1.43 1.22 to 1.68 o0.001*
DRI 0.07 0.18 0.17 1.08 0.76 to 1.53 0.677
* statistically significant
Table 2 - Comparison of the survival rate relative to the
Model for End-Stage Liver Disease, Model for Liver
Transplantation Survival and Donor Risk Index scores
based on the areas under the Receiver Operating
Characteristic curve for 1,006 liver transplants performed
in the state of Sa˜o Paulo between 2006 and 2009.
Time point and model N˚ deaths Area CI95% (area) p-value
7 days 117
MELD 0.59 0.54 to 0.65 0.001*
MLTS 0.59 0.54 to 0.64 0.002*
DRI 0.46 0.40 to 0.52 0.150
1 month 177
MELD 0.58 0.53 to 0.62 0.001*
MLTS 0.59 0.55 to 0.64 o0.001*
DRI 0.46 0.42 to 0.51 0.122
3 months 215
MELD 0.61 0.57 to 0.65 o0.001*
MLTS 0.62 0.58 to 0.66 o0.001*
DRI 0.47 0.42 to 0.51 0.155
6 months 243
MELD 0.61 0.57 to 0.65 o0.001*
MLTS 0.60 0.56 to 0.65 o0.001*
DRI 0.47 0.42 to 0.51 0.107
1 year 264
MELD 0.60 0.56 to 0.64 o0.001*
MLTS 0.60 0.56 to 0.64 o0.001*
DRI 0.48 0.44 to 0.52 0.312
2 years 274
MELD 0.60 0.56 to 0.64 o0.001*
MLTS 0.60 0.56 to 0.64 o0.001*
DRI 0.49 0.45 to 0.53 0.724
* statistically significant
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liver transplantation and was not a donor after cardiac death
(DCD). In addition, the ideal donor had stayed o4 days in
intensive care, had an average blood pressure Z60 mmHg,
had no requirement for vasoactive drugs, and had laboratory
findings within the following limits: bilirubin r2 mg/dl,
alanine level o170 U/L, aspartate aminotransferase level
o140 U/L, and blood sodium level o160 mEq/L (2,9,21).
In our study, the DRI was not a good indicator of post-
transplantation mortality (CoxPH=1.08, p=0.677) or survival
(the areas under the ROC curve for 3-month and 1-year
survival had c-statistic values of 0.47 and 0.48, respectively;
these values were always o0.5). These negative findings
might be due to the heterogeneity of the Brazilian popula-
tion. Additionally, there may have been influential factors
that are not included in the DRI.
Few studies have analyzed the DRI as a post-transplanta-
tion survival index. However, Northup et al. investigated the
effect of an expanded set of donor criteria on retransplanta-
tion outcomes and developed an index based on the DRI.
Among the 1327 retransplant recipients examined, 611 (46%)
received a graft involving at least one expanded criterion.
They found that the DRI was a good indicator of post-
retransplantation survival (HR 2.19, CI95%=1.63–2.94;
po0.0001). Moreover, when the cause of graft failure was
included in the DRI, the prediction strength significantly
increased (HR 2.49, CI95%=1.89–3.27; po0.0001) (22).
The interactions between the DRI and the MELD have
been examined by some authors. In a study involving 1,090
transplants, Bonney et al. (23) found that patients with low
to intermediate MELD scores (i.e., patients with low to
moderate disease severity) only experienced a survival
benefit from transplantation when they received an organ
corresponding to a low DRI score, whereas recipients with a
high MELD score (severely ill) benefited from transplanta-
tion regardless of whether the donor organ corresponded to
a low or high DRI score. These results partially corrobo-
rated those of Schaubel et al. (24), who demonstrated that
patients with a high DRI score that received a transplant
had a mortality rate 3.5-fold greater than those that
remained on the waiting list. These results further estab-
lished that severely ill patients with a high MELD score
benefited from receiving an organ, even from a donor with
a high DRI score, whereas less gravely ill patients with a
low MELD score did not benefit from receiving an organ
from a donor with a high DRI score compared to remaining
on the waiting list.
To date, no extensive information is available regarding
the relationship between the characteristics of liver donors
and the post-transplantation survival of organ recipients.
However, this issue should be considered further, as it could
become an important consideration for transplant teams and
transplant candidates as decisions are made to optimize
organ allocation and organ acceptance.
MLTS
Transplant outcomes depend on the interaction of the
following three factors: the donor, the recipient, and the
perioperative period. The MLTS is a mathematical model
created by Ghobrial et al. (12) that is based on these factors.
The MLTS uses multivariate statistical analysis to indepen-
dently determine the impact of these factors on transplant
recipient survival. In this study, we constructed ROC curves
for the MLTS data and found that for all time intervals
examined, the areas under the ROC curve were higher
than 0.5. The areas under the ROC curve for our MELD and
MLTS datasets were not significantly different (Table 2).
Prior studies by Jacob et al. (13,14) produced MLTS c-statistic
values for 3-month, 6-month, and 1-year post-transplanta-
tion survival of 0.57, 0.57, and 0.56, respectively, indicating a
weak discriminatory power for predicting survival in their
study population.
Scores to predict survival after liver transplantation are
indeed an interesting and current topic, and one limitation of
our study was not including and comparing the most
recently developed scores, such as the Survival Outcome
Following Liver Transplantation score, the balance of risk
score, and the multi-layer perception network, with the
examined models (25–27). These scores are not widely used
to predict survival after liver transplantation; however, we
believe that further studies should be conducted to create
scores in each country or region or even to adapt the already
existing scores to produce scores that are more appropriate
for the characteristics of each local setting.
In conclusion, the present results for 1,006 liver transplants
performed between 2006 and 2009 using cadaver donors in
the state of São Paulo, Brazil, showed that the MELD and the
MLTS display a similar ability to predict death after a liver
transplant and that the DRI does not predict mortality after a
Table 3 - Multivariate survival analysis of the parameters used to calculate the Model for End-Stage Liver Disease and
Model for Liver Transplantation Survival scores as independent variables for 1,006 liver transplants performed in the
state of Sa˜o Paulo between 2006 and 2009.
Variable b SEw Wald X2 CoxPH CI95% (CoxPH) p-value
MELD
Log-creatinine (mg/dL) 0.17 0.09 3.69 1.19 1.00 to 1.42 0.055
Log-total bilirubin (mg/dL) 0.12 0.06 4.18 1.13 1.01 to 1.27 0.041*
INR 0.18 0.16 1.27 1.19 0.88 to 1.62 0.260
MLTS
Recipient age 0.01 0.00 1.92 1.01 1.00 to 1.02 0.166
Donor age 0.00 0.00 0.02 1.00 0.99 to 1.01 0.897
Log-creatinine (mg/dL) 0.38 0.22 3.06 1.46 0.96 to 2.22 0.080
Log-total bilirubin (mg/dL) 0.26 0.13 3.92 1.29 1.00 to 1.67 0.048*
Cold ischemia duration (hours) 0.05 0.02 4.74 1.05 1.00 to 1.09 0.029*
Warm ischemia duration (min) 0.01 0.00 11.88 1.01 1.00 to 1.02 0.001*
Log-prothrombin time (s) 0.01 0.00 2.89 1.01 1.00 to 1.01 0.089
Retransplant 0.53 0.20 7.15 1.70 1.15 to 2.50 0.008*
w SE, standard error
* statistically significant
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liver transplant. In principle, a model that uses recipient,
donor, and surgical team variables, such as the MLTS, would
be expected to be preferable to a model based solely on the
donor variables (i.e., the DRI) or the recipient variables (i.e.,
the MELD). However, the present results showed that the
MLTS did not provide more reliable information than the
MELD. Therefore, we suggest that it would be preferential to
continue to employ a simpler model involving fewer
variables, such as MELD, rather than adopt a more complex
model involving more variables, such as the MLTS, while
creating a new local or regional score.
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